cyrilzakka/clinical-trials huggingface dataset:
Ethnopharmacological Studies in Oral Medicine

These are ethnomedicine studies of plants used by rural and indigenous peoples for pain and oral inflammation relief.

These are ethnomedicine studies of plants used by rural and indigenous peoples for pain relief in Central and South America.

Eligibility Criteria:
Inclusion Criteria:

* Patients who use plants to relieve oral pain, inflammations, ulcers, and tumors
A User Study of the Soniflow System for Nasal Congestion Relief

The Soniflow System consists of an acoustic vibrational headband paired with a Smartphone App to provide rapid relief of nasal congestion.

The Soniflow System is a non-invasive device to provide rapid relief of nasal congestion. It consists of a headband with ultrasound transducers (hardware) coupled to a Smartphone application (software).

Eligibility Criteria:
Inclusion Criteria:

1. Subject is \>18 years of age
2. Subject has had moderate to severe symptoms of nasal congestion for \>3 months (TNSS rating of 2 or 3)
3. Subject has signed IRB-approved informed consent form

Exclusion Criteria:

1. Subject has neurologic comorbidities
2. Subject has active dental infection
3. Subject is pregnant
4. Subject has implanted intracranial electrostimulation device(s) (e.g. cochlear implant, deep brain stimulator)
5. Subject has undergone sinonasal or craniomaxillofacial surgery within the lats 3 months
6. Subject has been diagnosed with intracranial hemorrhage within the last 6 months
7. Subject has open scalp wounds or rashes
8. Subject has any history of craniotomy without replacement of a bone flap
9. Subject has elevated sensitivity to sound
10. Any physical condition that in the investigator's opinion would prevent adequate study participation or pose increased risk
Influence of Diet and Lifestyle Factors on the Results of the IVF

The purpose of this study is study the possible relationship between various lifestyle habits of men and women (age, body mass index, diet, exercise, alcohol, tobacco, coffee, etc..) and live birth rate after in vitro fertilization-intracytoplasmatic injection (IVF-ICSI).

It is a prospective study of couples with primary or secondary infertility, with indication for IVF. The main objective is to relate different lifestyle factors (age, BMI, physical activity, tobacco consumption, alchol, drugs, work and diet) with reproductive outcomes obtained in terms of total oocytes, M II, fertilization and implantation rates pregnancy and abortion rates and live birth. It also attempts to correlate the different habits of life in men with seminal parameters. For this, both members of the pair separately should answer a validated questionnaire before beginning the therapeutic process.

Eligibility Criteria:
Inclusion Criteria:

* Couples who want a pregnancy
* Mediterranean or Caucasian Ethnicity.
* Infertility to justify treatment with IVF / ICSI-TEI.
* First cycle of IVF / ICSI.
* Between 18 and 37 years (inclusive)
* Presence of one or both ovaries and uterus can withstand embryo implantation and pregnancy.
* Body mass index (BMI) \<40.
* Absence of pregnancy before starting ovarian stimulation.
* Having given their written consent.

Exclusion Criteria:

* Clinically important disease.
* Inclusion in previous cycles of assisted reproduction.
* Unexplained vaginal bleeding.
* Any contraindication to become pregnant.
* Known allergy to preparations of gonadotropins or its excipients.
* Patients undergoing oocyte donation cycles -
Intrathecal Injection Pemetrexed And Bevacizumab in Patients With Leptomeningeal Metastases in NSCLC

This is a prospective, single-arm, phase Ia clinical study, which was designed to evaluate the efficacy and safety of Pemetrexed Combined With Bevacizumab Intrathecal Injection in Patients With Leptomeningeal Metastases in NSCLC.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years;
* ECOG PS score 0-3. ECOG PS score 2 or 3 should be due to leptomeningeal metastases.
* Patients with pathologically diagnosed non-small cell lung cancer with cerebrospinal fluid and/or MRI diagnosis of leptomeningeal metastasis(LM);
* Unsatisfactory efficacy of LM,which defined as disease progression in LM,or LM-related neurological progression, while patients received standard systemic anti-tumor treatment;
* Expected survival time ≥ 1 month;
* The laboratory test results meet the following criteria:Hemoglobin ≥ 90 g/L, neutrophil count ≥ 1.5 × 10\^9/L, platelet count ≥ 100 × 10\^9/L; Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN ; Creatinine≤ 2.0 × ULN,or Creatinine clearance rate (CrCl) ≥ 50 mL/min;
* Females of child-bearing potential agree to use contraception during the study period and for 6 months after the completion of the study; patients who have had a negative serum or urine pregnancy test within seven days prior to enrollment in the study and who are not breastfeeding; and males agreeing to use contraception during the study period and for 6 months after the completion of the study;
* Understand and sign the informed consent form.

Exclusion Criteria:

* Positive for human immunodeficiency virus (HIV) ;
* History of allergy to pemetrexed or bevacizumab;
* History of pemetrexed and/or bevacizumab intrathecal Injection;
* Presence of contraindication of bevacizumab:

  1. Uncontrolled hypertension(systolic pressure≥150mmHg，or diastolic pressure≥100mmHg；History of hypertensive crisis or hypertensive encephalopathy;
  2. Urine protein≥2+,or 24-hour urine protein≥2g；
  3. Unstable angina pectoris, symptomatic congestive heart failure,myocardial infarction within 6 months before enrollment, severe vascular disease, severe uncontrolled arrhythmia;
  4. Major hemoptysis within the past 1 month; History of coagulation disorders;
  5. Presence of serious non-healing wounds, ulcers, or bone fractures
  6. Presence of abdominal fistula, gastrointestinal perforation, or gastrointestinal tract obstruction;
  7. Presence of macrovascular invasion；
  8. Some neurological disorders unrelated to tumors，such as intracranial infection,cerebral hemorrhage,cerebral infarction,encephalitis;
* Brain/spinal cord radiation therapy within 1 week before enrollment;
* Pregnant and lactating female;
* Refuse to use contraception during the study period;
* Individuals considered by the investigator to be unsuitable for enrollment.
Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia

The purpose of this study is to determine that the efficacy of the sustained release (SR) formulation of quetiapine (Seroquel) is not inferior to the immediate release (IR) formulation.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.


Eligibility Criteria:
Inclusion Criteria:

* A stable dose of quetiapine IR between 300 and 800 mg/day within 4 weeks prior to the enrolment visit (Visit 1) as judged by the investigator.
* Female patients of childbearing potential must have a negative serum pregnancy test at enrolment and be willing to use a reliable method of birth control, ie, barrier method, oral contraceptive, implant, dermal contraception, long-term injectable contraceptive, intrauterine device, or tubal ligation during the study.
* Able to understand and comply with the requirements of the study, as judged by the investigator.

Exclusion Criteria:

* Meeting the criteria for any other (than schizophrenia) Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV) Axis I diagnosis, concomitant organic mental disorder or mental retardation.
* Patients with substance abuse or dependence, as defined by DSM-IV, and not in full remission. A urine drug screen test will be performed. The investigator will evaluate the results along with medical history to determine if the patient meets DSM-IV criteria for substance abuse or dependence.
* Risk of transmitting human immunodeficiency virus (HIV) or hepatitis B, via blood or other body fluids, as judged by the investigator.
* Patients who, in the opinion of the investigator, pose an imminent risk of suicide or a danger to self or others.
Safety, Tolerability, PK, PD, Immunogenicity and Efficacy of TWP-102 in Patients With Advanced Malignancies.

This is a multi-center, phase I, open clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and efficacy of TWP-102 injection in patients with advanced malignancies. This study consists of two parts, including a dose escalation study and a dose expansion study. The criteria for dose escalation will be based on the Bayesian optimal interval (BOIN) design with sequentially enrolled cohorts.


Eligibility Criteria:
Inclusion Criteria:

* Pathologically confirmed advanced malignancies that failed, or not suitable for standard treatments;
* At least 1 measurable lesion.
* ECOG score 0 or 1;
* Life expectancy of ≥ 3 months;

Exclusion Criteria:

* Known hypersensitivity to any ingredient of TWP-102;
* Receiving any anti-cancer drugs within 4 weeks;
* History of serious systemic diseases;
* History of serious autoimmune diseases;
* Persistent toxicity of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade \> 1 severity that is related to prior anti-cancer therapy. (except alopecia)
* Pregnancy or lactating women.
Effect of Inhaled Albuterol in Pulmonary Hypertension

The purpose of the present pilot study is to test the hypothesis that in patients with group 1 pulmonary arterial hypertension (PAH) who are on regular oral pulmonary vasodilator therapy, inhaled albuterol causes transient pulmonary vasodilation.


Eligibility Criteria:
Inclusion Criteria:

* A Mean Pulmonary Artery Pressure \>25mmHg, Pulmonary Vascular Resistance \>3 wood/units and pulmonary arterial wedge pressure \<15mmHg, as documented by right heart catheterization within the last 3 years
* Regular use of oral pulmonary vasodilators

Exclusion Criteria:

* Presence of chronic respiratory disease (as documented by prior lung imaging and pulmonary function tests), cardiovascular disease (as documented by prior echocardiography and/or left heart catheterization), thromboembolic PAH (as documented by pulmonary angiography)
* women of childbearing potential who do not use accepted birth- control measures
* pregnant and breast-feeding women
* respiratory infection within 4 weeks of testing
* A systemic systolic arterial BP\> 150 and/or diastolic arterial BP\>100 on the experiment day
* A resting O2 saturation of \< 90%
* Current smoking
* BMI \>35 kg/m2 and/or a diagnosis of obstructive sleep apnea
* Use of inhaled or intravenous pulmonary vasodilators
Neurological Outcomes After In-Hospital Cardiac Arrest

Little is known about the long-term neurological outcomes after in-hospital cardiac arrest (IHCA). It is also not known whether withdrawal of life-sustaining measures will influence rates of survivors with poor neurological status. Currently, withdrawal of care in comatose patients after cardiac arrest is strongly forbidden by law in Korea. However, a new legislation on allowing withdrawal of care will come into effect since early 2018 in Korea. The investigators aim to determine 1) long-term neurological outcomes in patients who developed IHCA, 2) whether early neurological status can predict late neurological status after IHCA, and 3) whether the proportion of IHCA survivors with good neurological outcomes will change since implementation of new legislation on withdrawal of care.

\<The schedule of assessment\>

* Day 0: Neurological examination (First examination will be performed within 2 hours after IHCA)
* Day1 - 7: Neurological examination
* Day7, 14, 21, 28: Neurological examination, CPC score
* Day90: CPC score, survival
* Day180: CPC score, survival
* Day 360: CPC score, survival

\<Cerebral Performance Category(CPC) score\>

* CPC 1: good cerebral performance
* CPC 2: Moderate cerebral disability(available for independent activities)
* CPC 3: Severe cerebral disability(dependent on others for daily support)
* CPC 4: Coma or vegetative state
* CPC 5: Brain death or death

\<Acronyms\>

* ACDU(Alert/Confused/Drowsy/Unresponsive) score
* FOUR(Full Outline of Unresponsiveness) score

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18
* In-hospital cardiac arrest
* Cardiopulmonary Resuscitation(CPR) code activation and/or neurology consultation for IHCA

Exclusion Criteria:

* Neither (CPR) code activation nor neurology consultation
* Development of IHCA during transition period
Healthcare Utilization and Outcomes of FinESS Treatment in the Office

A prospective, nonrandomized trial to evaluate postoperative healthcare resource utilization after maxillary balloon antrostomy using FinESS Sinus Treatment in the physician's office.

A prospective, nonrandomized trial to evaluate postoperative healthcare resource utilization after maxillary balloon antrostomy using FinESS Sinus Treatment in the physician's office. Also to demonstrate the long-term durability of FinESS Sinus Treatment performed in an office setting.

Eligibility Criteria:
Inclusion Criteria:

* 18 years or older
* Male or female subjects
* Diagnosis of rhinosinusitis (CT radiographic evidence and medical evaluation)
* Willing to comply with protocol requirements
* Able to provide consent

Exclusion Criteria:

* Hemophilia
* Cystic fibrosis
* Ciliary dysfunction
* Severe septal deviation causing obstruction of the ostiomeatal unit
* Pregnant females
A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS

The purpose of this study is to evaluate the efficacy and safety of cabergoline compared with levodopa in the treatment of patients with RLS.


Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of idiopathic RLS and had all 4 clinical manifestations of RLS
* Moderate to severe symptoms of RLS as indicated by an IRLSSG-RS total score greater than or equal to 10 and a severity at night score of greater than or equal to 4 on an 11-point RLS-6 rating scale
* No previous treatment for RLS or dissatisfaction with their current therapy

Exclusion Criteria:

* Not available
Mechanical Vs Chemomechanical Method For Calcium Hydroxide Removal

Type of study: Randomised Clinical trial To compare the effectiveness of Mechanical and Chemomechanical methods in the removal of Water-based Calcium hydroxide medicament from endodontic system.

Participants allocated in group A and B should be appointed for Endodontic treatment of Single rooted teeth diagnosed with Necrotic Pulp and Chronic Apical Periodontitis.

In group A, Calcium hydroxide medicament will be removed by using Mechanical method while in group B, Calcium hydroxide will be removed by using Chemomechanical method.

This study is aimed at comparing the effectiveness of Mechanical and Chemomechanical methods for removal of Intracanal medication. Water-based Calcium hydroxide is used as an Intracanal medicament in this study. Participants aged 18 years and above presenting to the Outpatient department of Operative dentistry and Endodontics, School of Dentistry, Shaheed Zulfiqar Ali Bhutto Medical University, Islamabad diagnosed with Necrotic Pulp with Chronic Apical Periodontitis will be randomly allocated in two groups A and B. On first visit, Root canal treatment will be initiated under rubber dam isolation. After locating canals, periapical radiograph for the working length will be taken. After working length has been confirmed, canal preparation will be done using Rotary file system. After canal has been prepared till working length, intracanal medicament is placed using Lentulospiral. Patient is recalled after 2 weeks. On next visit, Calcium hydroxide medicament will be removed by Mechanical method from group A. Mechanical method involves the use of Rotary file system for removal of medicament. In group B, Calcium hydroxide will be removed by using Chemomechanical method. Chemomechanical method involves the use of Sonic or Ultrasonic activation of irrigants for removal of medicament. After the removal of intracanal medicament, Periodical radiograph will be taken. Data will be taken on proforma and evaluation will be done for the effective removal of calcium hydroxide using a 4- point scoring system.

Eligibility Criteria:
Inclusion Criteria:

* SINGLE-ROOTED MAXILLARY AND MANDIBULAR TEETH
* NECROTIC TEETH WITH CHRONIC APICAL PERIODONTITIS
* STRAIGHT TO MODERATELY CURVED ROOT CANALS

Exclusion Criteria:

* PATIENTS WITH SYSTEMIC DISEASE
* PREGNANT AND IMMUNOCOMPROMISED PATIENTS
* TEETH WITH COMPROMISED PERIODONTAL HEALTH
* TEETH UNABLE TO BE RESTORED OR ISOLATED BY RUBBERDAM
Correlation Between Changes in Liver Stiffness and Preeclampsia as Shown by Fibroscan

Compare the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor.

Materials and Methods

The purpose of the study is to compare the Fibroscan results of preeclamptic women to normal controls and to find out if the changes are reversible after labor.

Materials and Methods This prospective observational case-control study will include 50 women admitted to the fetal-maternal Unit at 24 - 41 weeks gestation and diagnosed with mild/severe preeclampsia. Preeclampsia is diagnosed as a new onset of hypertension over 140/90, at least two measurements at least four hours apart, and proteinuria (≥+1 in dipstick or \>300 mg/24 hr) after 20 weeks of gestation in a previously normotensive woman.

A control group will consist 100 normotensive women with normal pregnancy outcomes who were admitted to our fetal-maternal unit during the same period. Demographic, clinical, laboratory and sonographic data for the women participating will be collected from their chart. All patients diagnosed with preeclampsia will undergo the following workup: sign and symptoms evaluation, blood pressure follow up, 24-hour protein excretion in grams per day, complete blood count, hepatic function test: AST, ALT and coagulation study, HBA1C, coagulation function test and fibrotest. The Fibroscan test will be performed by a trained hepatologist, who was blind to the women diagnosis. The fibroscan test will be done during the admission after the diagnosis of preeclampsia, after delivery and 6 weeks post-partum.

Commonly used cutoffs are \>7 kPa for significant fibrosis. Statistical analysis will be performed with SPSS using Mann Whitney test. Continuous variables will be analyzed using the student's T test and categorical variables were analyzed using 2. Statistical significance was set at a P value of \< 0.05. The local institutional review board approved this study.

Eligibility Criteria:
Inclusion Criteria:

- Fetal-maternal Unit at 24 - 41 weeks gestation and diagnosed with mild/severe preeclampsia

Exclusion Criteria:

* Age less then 18
* Fetal-maternal less then 24 weeks
Chemical and Microbiological Exposure of Women on Dairy Cattle Farms

Although professionals working on dairy cattle farms come into contact with a wide range of chemicals and microbiological agents, little is known about this possible exposure, which occurs a priori via inhalation and skin contact.

The aim of this research is to gain a better understanding of this chemical and microbiological exposure, and this research focuses in particular on professional women working on dairy cattle farms , who may be in charge of specific activities not commonly carried out by professional men.

Exposure to pesticides, antiparasitic products and disinfectants will be the first substances to be investigated, followed by other chemical or particulate compounds present in everyday and professional environments. Exposure to these compounds will be measured by their presence in the urine, feces (if possible) and hair of around 60 participating women, as well as in bovine tuft/head hair and, if possible, air samples taken in milking buildings.


Eligibility Criteria:
Inclusion Criteria:

* Adult woman working on a dairy cattle farm in the "Grand Ouest" region of France
* Woman who speaks and understands French

Exclusion Criteria:

* working less than 20h/week in dairy farms
* Woman under legal protection
* unsigned consent form
LPR Fluorescence Pilot

Comparing the fluorescence signatures from mouthwash samples of patients with laryngopharyngeal reflux (LPR) and healthy volunteers.

The investigators aim to test if the biosensing platform Pandra, developed by Rosa Biotech, may be suitable to distinguish patients with LPR symptoms, both with and without objective evidence of gastroesophageal reflux disease (GORD), vs healthy volunteers due to their expected inflammation and cell changes in the laryngo-pharyngeal region. The investigators intend to analyse 20 samples of mouthwash solutions from each of the following groups:

A. Patients with symptoms of LPR and objective evidence of GORD B. Patients with symptoms of LPR and no objective evidence of GORD C. Healthy volunteer group

Eligibility Criteria:
Healthy Volunteers

Inclusion Criteria:

* Participant is Aged 18 or above
* Participant has capacity to understand written English
* Participant is not on regular prescription medicines
* Participant has an RSI score of 0
* Participant has a body mass index (BMI) of 18.5 - 34.9 kg/m2 (bounds included)

Exclusion Criteria:

* Participant has experienced any symptoms of LPR or GORD symptoms in the past year
* Participant has taken any medication for GORD/LPR in the past year (e.g. proton pump inhibitors, h2 antagonists, over the counter antacids)
* Participant has active oral disease
* Participant has a significant medical diagnosis

Patients with symptoms of LPR

Inclusion Criteria:

* Participant is Aged 18 or above
* Participant has capacity to understand written English
* Participant has an RSI score of \>13
* Participant has a body mass index (BMI) of 18.5 - 34.9 kg/m2 (bounds included
* Participant has been referred for 24hr ambulatory pH-impedance monitoring

Exclusion Criteria:

* Participant has active oral disease
* Participant has other ongoing health problems that could account for their LPR symptoms.
* Participant has NOT undergone nasoendoscopy within last 6 months OR does not have one scheduled within next 6 weeks
* Previous antireflux surgery (e.g. fundoplication or magnetic sphincter augmentation)
* Previous bariatric surgery (e.g. gastric bypass or sleeve gastrectomy)
Arterio-Venous Fistula Audit. Successful Utilisation Rates of Arterio-Venous Fistulae for Haemodialysis at University Hospital Limerick

We wish to examine Arterio-Venous Fistula (AVF) and Arterio-Venous Graft (AVG) utilisation rates for Haemodialysis at University Hospital Limerick. We want to determine out of the AVF's that are surgically created, how many go on to be used as anticipated for haemodialysis treatments successfully.

There are over 2 million end-stage renal disease (ESRD) patients who require renal replacement therapy worldwide, and this is estimated to rise to over 5 million by 2030 (Liyanage et al. 2015).

Haemodialysis, used by the majority of ESRD patients, requires vascular access, where blood can be taken out of the body (via cannulation) and pumped through an external dialysis machine, which filters the blood of waste and excess fluid before being returned.

Arterio-venous fistula creation is the preferred vascular access for haemodialysis, but has a large failure rate in the maturation period (Colley et al. 2022). Failure is usually attributed to insufficient dilation of the vessel and/or stenosis, which results in inadequate blood flow rates for the purpose of haemodialysis (Dixon, 2006).

The purpose of this audit is to examine over a three year period how many of the individuals who had an AVF created are utilising it successfully for the purpose of haemodialysis as planned.

Eligibility Criteria:
Inclusion Criteria:

* Patients who had an AVF or AVG surgically created over the last three years at UHL who are undergoing haemodialysis treatments are suitable for inclusion.
* Dates for audit purposes are 1st April 2019 to 1st April 2022.

Exclusion Criteria:

* Patients outside of these set dates will be excluded.
* Patients who are not currently undergoing haemodialysis treatments are excluded.